Molecular detection of epidermal growth factor receptor in colorectal cancer: Does it still make sense?

Colorectal Disease

Volumn 13, Issue 5, 2011, Pages 542-548

  Nannini, M ^a   Pantaleo, M A ^a   Paterini, P ^a   Piazzi, G ^a   Ceccarelli, C ^a   La Rovere, S ^b   Maleddu, A ^a   Biasco, G ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Colorectal cancer; ELISA; Epidermal growth factor receptor; Immunohistochemistry; K RAS; Real time PCR

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; K RAS PROTEIN; MESSENGER RNA; MUTANT PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79953298405     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2010.02212.x     Document Type: Article

References (46)

1. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001; 37: S16-22.
2. Salomon DS, Bradt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptor in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
3. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001; 92: 1331-46.
4. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201.
5. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
6. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
7. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-64.
8. Dei Tos AP. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. Int J Biol Markers 2007; 22: S3-9.
9. Abd El All HS, Mishriky AM, Mohamed FA. Epidermal growth factor receptor in colorectal carcinoma: correlation with clinico-pathological prognostic factors. Colorectal Dis 2008; 10: 170-8.
10. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-86.
11. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25: 3238-45.
12. Cappuzzo F, Finocchiaro G, Rossi E, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008; 19: 717-23.
13. Italiano A, Follana P, Caroli FX, et al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2007; 15: 649-54.
14. Graziano F, Ruzzo A, Loupakis F, et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008; 26: 1427-34.
15. Piazzi G, Paterini P, Ceccarelli C, Pantaleo MA, Biasco G. Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa. Br J Cancer 2006; 95: 1525-8.
16. Personeni N, Hendlisz A, Gallez J, et al. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. Semin Oncol 2005; 6(Suppl. 9): S59-62.
17. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-45.
18. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-9.
19. Jhawer M, Goel S, Wilson AJ, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68: 1953-61.
20. Scartozzi M, Bearzi I, Pierantoni C, et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007; 25: 3930-5.
21. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-5.
22. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-9.
23. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-15.
24. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
25. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
26. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008; 26: (May 20 Suppl; abstr 2).
27. Tejpar S, Peeters M, Humblet Y, Vermorken JB, De Hertogh G, De Roock W, Nippgen J, von Heydebreck A, Stroh C, Van Cutsem E. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): the EVEREST experience (preliminary data). J Clin Oncol 2008; 26: (May 20 Suppl; abstr 4001).
28. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, Stroh C, Celik I, Koralewski P. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008; 26: (May 20 Suppl; abstr 4000).
29. Cervantes A, Macarulla T, Martinelli E, Rodriguez-Braun E, Ciardiello F, Stroh C, Nippgen J, Baselga J, Tabernero J. Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab+FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2008; 26: (May 20 Suppl; abstr 4129).
30. Di Fiore F, Van Cutsem E, Laurent-Puig P, Siena S, Frattini M, De Roock W, Lièvre A, Sartore-Bianchi A, Bardelli A, Tejparet S. Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series. J Clin Oncol 2008; 26: (May 20 Suppl; abstr 4035).
31. Spindler KL, Lindebjerg J, Nielsen JN, Olsen DA, Bisgård C, Brandslund I, Jakobsen A. Epidermal growth factor receptor analysis in colorectal cancer: a comparison of methods. Int J Oncol 2006; 29: 1159-65.
32. Pantaleo MA, Palassini E, Labianca R, Biasco G. Targeted therapy in colorectal cancer: do we know enough? Dig Liver Dis 2006; 38: 717.
33. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45.
34. Saltz L. Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity? Clin Colorectal Cancer 2005; 5(Suppl. 2): S98-100.
35. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Störkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissue: variation staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004; 52: 893-901.
36. Bhargava R, Chen B, Klimstra DS, et al. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer 2006; 106: 1857-62.
37. Penault-Llorca F, Cayre A, Arnould L, Bibeau F, Bralet MP, Rochaix P, Savary J, Sabourin JC. Is there an immunohistochemical techniques definitively valid in epidermal growth factor receptor assessment? Oncol Rep 2006; 16: 1173-9.
38. Derecskei K, Moldvay J, Bogos K, Tímár J. Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues. Pathol Oncol Res 2006; 12: 243-6.
39. Vallböhmer D, Zhang W, Gordon M, et al. Molecular determinants of Cetuximab efficacy. J Clin Oncol 2005; 23: 3536-44.
40. Sauer T, Guren MG, Dueland S. Demonstration of EGFr gene loss in colorectal carcinoma by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFr therapy? Histopathology 2005; 47: 560-4.
41. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y. Protein overexpression and gene amplification of HER-2 and EGFr in colorectal cancers: an immunohistochemical and fluoroscent in situ hybridization. Mod Pathol 2004; 17: 895-904.
42. Shia J, Klimstra DS, Li AR, et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 2005; 18: 1350-6.
43. Antonacopoulou AG, Tsamandas AC, Petsas T, Liava A, Scopa CD, Papavassiliou AG, Kalofonos HP. EGFR, HER-2 and COX-2 levels in colorectal cancer. Histopathology 2008; 53: 698-706.
44. Pantaleo MA, Nannini M, Maleddu A, et al. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol 2009; 20: 213-26.
45. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications foe treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004; 22: 4772-8.
46. Italiano A, Saint-Paul MC, Caroli-Bosc FX, François E, Bourgeon A, Benchimol D, Gugenheim J, Michiels JF. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol 2005; 16: 1503-7.